Key clinical point: One in four men in England and Wales with advanced prostate cancer receives chemotherapy.
Major finding: On average, 27% of men with advanced prostate cancer received docetaxel, ranging from 0% to 39% across National Health Service care providers in England.
Study details: The data come from the National Prostate Cancer Audit 2019 annual report for England and Wales.
Disclosures: Ms. Wise had no financial conflicts to disclose.
Wise J. BMJ. 2020. doi:10.1136/bmj.m120.